Skip to Content

Tabrecta (capmatinib) Disease Interactions

There are 4 disease interactions with Tabrecta (capmatinib):

Moderate

Capmatinib (Includes Tabrecta) ↔ liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease, Hyperbilirubinemia

Capmatinib is primarily metabolized by CYP450 3A4 and aldehyde oxidase and its use may cause hepatotoxicity. Assess liver function tests, including ALT, AST, and total bilirubin before administering capmatinib, every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or bilirubin. Caution when using this agent in patients with liver disorder or a disorder of bilirubin metabolism. Withhold, reduce the dose, or permanently discontinue capmatinib based on severity of adverse reactions. No clinically significant effects on the pharmacokinetic parameters of capmatinib were identified in patients with mild, moderate or severe hepatic impairment.

Moderate

Capmatinib (Includes Tabrecta) ↔ lung disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Pulmonary Impairment

The use of capmatinib may cause interstitial lung disease (ILD)/pneumonitis. Exercise care when using this agent in patients with disorders of the lung. It is recommended to monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Immediately withhold treatment with capmatinib in patients with suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis are identified.

Moderate

Capmatinib (Includes Tabrecta) ↔ photosensitivity

Moderate Potential Hazard, Moderate plausibility. Applies to: Skin Cancer, History - Skin Cancer

The use of capmatinib may cause photosensitivity reactions. Exercise care when using this agent in patients predisposed to photosensitivity reactions or with a history of skin cancer. It is recommended that patients use precautionary measures against ultraviolet exposure such as use of sunscreen or protective clothing during treatment with capmatinib. Advise patients to limit direct ultraviolet exposure during treatment.

Moderate

Capmatinib (Includes Tabrecta) ↔ renal dysfunction

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

No clinically significant effects on the pharmacokinetic parameters of capmatinib were identified in patients with mild to moderate renal impairment. Therefore, no dosage adjustment is recommended in patients with mild or moderate renal impairment. Exercise care when using capmatinib in patients with severe renal impairment as it has not been studied in these patient population.

Tabrecta (capmatinib) drug interactions

There are 251 drug interactions with Tabrecta (capmatinib)

Tabrecta (capmatinib) alcohol/food interactions

There is 1 alcohol/food interaction with Tabrecta (capmatinib)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.